Replies to post #230313 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

The advantage of a provisional approval is that the company records data from patients taking the drug in the real world, so after (or "if" if you prefer) 2-73 is approved for the drugs now in trial with continued positive results I would expect the company would simply have to make a scientific case for each disease and then go into PA and reporting those results.

Again, SLEEP will be sufficient justification.

Also, since there is a real world population being watched, if there is ANY suspicion of toxicity patients can be analyzed 5-10-20 years into the future. Birth defects could also be identified in the second generation. This is 21st century medicine.

[anders2211]

Hi TempePhil,

Thank you for your kind reply.
I hope your relative and our son will benefit from 273. I fully agree with your vision of 273 and autism.

Yes there is plenty of reasons to be hopeful!
In The Netherlands under very strict conditions off label use, is permitted. As soon as 273 is allowed in any country (Australia?) we will travel there if needed we stay there as long as it takes to get 273 :-)

If there will be an autism trial with 273, we are seriously considering to emigrate to that part of the world. However I doubt Anavex will start such a trial anytime soon.

As Jimmy pointed out, patents are written as broadly as possible, and frequently before there is actual proof that the invention works. That is what anavex does, and then writes more patents as more is learned.

Yes that explanation is of course logically the most obvious.

Thank you my friend! Have a wonderful day.